B6-hOSMR Mouse
Product Name
B6-hOSMR Mouse
Product ID
C001841
Strain Name
C57BL/6NCya-Osmrtm1(hOSMR)/Cya
Backgroud
C57BL/6NCya
Status
When using this mouse strain in a publication, please cite “B6-hOSMR Mouse (Catalog C001841) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
Gene Alias
OSMRB, PLCA1, IL-31RB, OSMRbeta, IL-31R-beta
NCBI ID
Chromosome
Chr 5
MGI ID
Datasheet
Strain Description
The oncostatin M receptor (OSMR) gene encodes the OSMRβ protein subunit, which is widely expressed in the skin (in keratinocytes), liver (in hepatocytes), and various immune cells. This protein subunit forms heterodimeric complexes with the signal transduction subunit gp130 (or IL-31Rα), serving as functional receptors for two key inflammatory cytokines: oncostatin M (OSM) and interleukin-31 (IL-31), respectively. Upon binding of these cytokines to their receptors, the JAK/STAT signaling pathway is primarily activated, thereby regulating multiple critical biological processes, including inflammatory responses, immune responses, and tissue regeneration. Dysregulation of the OSMR signaling pathway is closely linked to the pathophysiological processes of various diseases. In dermatology, mutations in the OSMR gene are the direct cause of primary localized cutaneous amyloidosis (PLCA), a rare hereditary disorder [1]. Meanwhile, excessive activation of this pathway (particularly the IL-31 axis) acts as a core driver of pruritus and inflammation in chronic inflammatory skin diseases such as atopic dermatitis [2]. In oncology, OSMR-based therapies hold potential for treating various cancers, including cervical squamous cell carcinoma and lung adenocarcinoma [3-4]. Given its central role in inflammation-driven processes and the tumor microenvironment, the OSMR signaling pathway has emerged as a key target for drug development.
B6-hOSMR mouse is a humanized model constructed by replacing the coding sequences of exon 2 and partial intron 2 sequence of the murine Osmr gene with the Kozak-OSMR chimeric CDS-3'UTR of mouse Osmr-WPRE-BGH pA expression cassette. This model is applicable to mechanistic research on inflammatory diseases (e.g., rheumatoid arthritis, atopic dermatitis), cancers (cervical squamous cell carcinoma, lung adenocarcinoma, pancreatic cancer), cardiovascular diseases (e.g., atherosclerosis), liver diseases (e.g., fibrosis), and hematopoietic and bone marrow-related disorders. It also supports the screening, development, and safety evaluation of OSMR-targeted drugs.
Reference
Arita K, South AP, Hans-Filho G, Sakuma TH, Lai-Cheong J, Clements S, Odashiro M, Odashiro DN, Hans-Neto G, Hans NR, Holder MV, Bhogal BS, Hartshorne ST, Akiyama M, Shimizu H, McGrath JA. Oncostatin M receptor-beta mutations underlie familial primary localized cutaneous amyloidosis. Am J Hum Genet. 2008 Jan;82(1):73-80.
Kunimura K, Fukui Y. The molecular basis for IL-31 production and IL-31-mediated itch transmission: from biology to drug development. Int Immunol. 2021 Nov 25;33(12):731-736.
Caffarel MM, Coleman N. Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma. J Pathol. 2014 Mar;232(4):386-90.
Chen D, Chu CY, Chen CY, Yang HC, Chiang YY, Lin TY, Chiang IP, Chuang DY, Yu CC, Chow KC. Expression of short-form oncostatin M receptor as a decoy receptor in lung adenocarcinomas. J Pathol. 2008 Jul;215(3):290-9.
Strain Strategy
The coding sequences of exon 2 plus partial intron 2 of mouse Osmr will be replaced with the Kozak-OSMR chimeric CDS-3'UTR of mouse Osmr-WPRE-BGH pA cassette.
Figure 1. Gene editing strategy of B6-hOSMR mice.
Application Area
Screening, development, and preclinical evaluation of OSMR-targeted drugs;
Research on the pathological mechanisms and therapeutic approaches of inflammatory diseases, such as rheumatoid arthritis (RA), atopic dermatitis (AD), and inflammatory bowel disease (IBD);
Research on the pathological mechanisms and therapeutic approaches of cancers, including cervical squamous cell carcinoma, lung adenocarcinoma, and pancreatic cancer;
Research on cardiovascular diseases (e.g., atherosclerosis);
Research on liver diseases (e.g., fibrosis);
Research on hematopoietic and bone marrow-related disorders.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.